News | March 11, 2026
Alcon launches Hydrus Microstent in India to transform glaucoma care
The Hydrus Microstent stands out as the first and only MIGS device backed by five-year clinical outcomes
The Hydrus Microstent stands out as the first and only MIGS device backed by five-year clinical outcomes
Indomo’s ClearPen system combines a proprietary self-injection device and microneedle with a modernized triamcinolone acetonide formulation
Fenebrutinib has the potential to become the first and only high-efficacy oral, brain-penetrant treatment for both RMS and PPMS, showing a profound benefit on relapsing and progressive disease biology
Dawson joins Roche from the Peter MacCallum Cancer Centre, where he serves as Associate Director of Research
The approval follows the pivotal Phase III ARANOTE trial, which demonstrated that darolutamide plus ADT cut the risk of radiological progression or death by 46% compared to placebo plus ADT
Study published in laboratory investigation, the official journal of the United States and Canadian Academy of Pathology
Bertozzi currently serves as the Baker Family Director of Sarafan ChEM-H, Anne T. and Robert M. Bass Professor at Stanford University, and Investigator of the Howard Hughes Medical Institute
Ilumya is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials
Soficitinib is a potent and selective TYK2 inhibitor under development for multiple T-cell mediated autoimmune disorders
Subscribe To Our Newsletter & Stay Updated
